Apogee Therapeutics (APGE) reported a 2024 net loss Monday of $182.1 million, widening from a loss of $84 million a year earlier.
Analysts polled by FactSet expected a loss of $177.9 million.
At the end of the year, cash, cash equivalents and marketable securities were $731.1 million. The company said it expects its existing cash, cash equivalents and marketable securities to allow it to fund its operating expenses into Q1 2028.
Apogee shares were up 1.5% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。